Matisse Pharmaceuticals Raises €14 Million in Series A Funding
Matisse Pharmaceuticals B.V., based in Geleen, Limburg, Netherlands, has successfully closed a €14 million Series A funding round. The company, which is focused on developing treatments that neutralize cytotoxic histones to save lives, aims to advance its lead candidate, isupartob sodium, through Phase 2 clinical trials for sepsis treatment.
Investors and Financial Details
The funding round saw participation from institutional investors such as Brightlands Venture Partners and LIOF, alongside private investors and company management. This influx of capital will support the company’s efforts in clinical trials and other operational activities.
Use of Funds
The primary focus of the newly raised funds will be the execution of the Phase 2 clinical trials for isupartob sodium. This development stage is crucial for Matisse Pharmaceuticals as it seeks to gather the necessary clinical data to progress to the next stages of development. Additionally, the funds will aid in regulatory, manufacturing, and operational activities.
Leadership Perspective
Marcel Jacobs, Chief Executive Officer of Matisse Pharmaceuticals, expressed gratitude for the continued support from existing shareholders and welcomed new investors. "Their support enables us to focus on what matters most: Successfully completing our Phase 2 clinical trial in sepsis patients," Jacobs stated.
Matisse Pharmaceuticals is poised to make significant strides in addressing the unmet medical needs in sepsis treatment, with its innovative therapeutic approach.